Which has stronger earnings and valuation, INFU or TALK?

Talkspace has higher revenue and earnings than InfuSystem. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InfuSystem $143.34M 1.71 $870K $0.41 29.63 Talkspace $228.87M 3.84 $7.79M N/A N/A

Is INFU or TALK more profitable?

InfuSystem has a net margin of 1.12% compared to Talkspace's net margin of 0.08%. InfuSystem's return on equity of 2.78% beat Talkspace's return on equity. Company Net Margins Return on Equity Return on Assets InfuSystem 1.12% 2.78% 1.41% Talkspace 0.08% 0.17% 0.14%

Does the media refer more to INFU or TALK?

In the previous week, InfuSystem and InfuSystem both had 1 articles in the media. InfuSystem's average media sentiment score of 1.63 beat Talkspace's score of 0.00 indicating that InfuSystem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InfuSystem 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Talkspace 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to INFU or GMRS?

In the previous week, GMR Solutions had 6 more articles in the media than InfuSystem. MarketBeat recorded 7 mentions for GMR Solutions and 1 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.63 beat GMR Solutions' score of 1.34 indicating that InfuSystem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InfuSystem 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive GMR Solutions 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor FLGT or INFU?

In the previous week, Fulgent Genetics had 2 more articles in the media than InfuSystem. MarketBeat recorded 3 mentions for Fulgent Genetics and 1 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.63 beat Fulgent Genetics' score of 1.62 indicating that InfuSystem is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive InfuSystem 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor INFU or SRTA?

In the previous week, Strata Critical Medical had 1 more articles in the media than InfuSystem. MarketBeat recorded 2 mentions for Strata Critical Medical and 1 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.63 beat Strata Critical Medical's score of 0.93 indicating that InfuSystem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InfuSystem 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Strata Critical Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, INFU or SBC?

SBC Medical Group has higher revenue and earnings than InfuSystem. SBC Medical Group is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InfuSystem $143.34M 1.71 $870K $0.41 29.63 SBC Medical Group $173.61M 2.64 $50.99M $0.47 9.49

InfuSystem (INFU) Competitors

$12.15 +0.03 (+0.25%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$12.13 -0.02 (-0.16%)

As of 09/11/2026 07:30 PM Eastern

Compare

INFU vs. TALK, GMRS, FLGT, SRTA, and SBC

Should you buy InfuSystem stock or one of its competitors? InfuSystem's main competitors and comparable companies include Talkspace (TALK), GMR Solutions (GMRS), Fulgent Genetics (FLGT), Strata Critical Medical (SRTA), and SBC Medical Group (SBC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does InfuSystem compare to Talkspace?

InfuSystem (NYSE:INFU) and Talkspace (NASDAQ:TALK) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

Talkspace has higher revenue and earnings than InfuSystem.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$143.34M	1.71	$870K	$0.41	29.63
Talkspace	$228.87M	3.84	$7.79M	N/A	N/A

InfuSystem has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, Talkspace has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

InfuSystem currently has a consensus target price of $16.67, indicating a potential upside of 37.17%. Talkspace has a consensus target price of $5.56, indicating a potential upside of 5.95%. Given InfuSystem's stronger consensus rating and higher probable upside, research analysts clearly believe InfuSystem is more favorable than Talkspace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Talkspace	1 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

71.1% of InfuSystem shares are owned by institutional investors. Comparatively, 57.4% of Talkspace shares are owned by institutional investors. 10.8% of InfuSystem shares are owned by insiders. Comparatively, 23.5% of Talkspace shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, InfuSystem and InfuSystem both had 1 articles in the media. InfuSystem's average media sentiment score of 1.63 beat Talkspace's score of 0.00 indicating that InfuSystem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InfuSystem	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Talkspace	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InfuSystem has a net margin of 1.12% compared to Talkspace's net margin of 0.08%. InfuSystem's return on equity of 2.78% beat Talkspace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Talkspace	0.08%	0.17%	0.14%

Summary

InfuSystem beats Talkspace on 9 of the 13 factors compared between the two stocks.

How does InfuSystem compare to GMR Solutions?

InfuSystem (NYSE:INFU) and GMR Solutions (NYSE:GMRS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

InfuSystem currently has a consensus price target of $16.67, suggesting a potential upside of 37.17%. GMR Solutions has a consensus price target of $18.78, suggesting a potential upside of 46.59%. Given GMR Solutions' higher possible upside, analysts plainly believe GMR Solutions is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
GMR Solutions	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

InfuSystem has higher revenue and earnings than GMR Solutions. GMR Solutions is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$143.34M	1.71	$870K	$0.41	29.63
GMR Solutions	N/A	N/A	N/A	-$1.56	N/A

In the previous week, GMR Solutions had 6 more articles in the media than InfuSystem. MarketBeat recorded 7 mentions for GMR Solutions and 1 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.63 beat GMR Solutions' score of 1.34 indicating that InfuSystem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InfuSystem	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
GMR Solutions	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.1% of InfuSystem shares are held by institutional investors. 10.8% of InfuSystem shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

InfuSystem has a net margin of 1.12% compared to GMR Solutions' net margin of 0.00%. InfuSystem's return on equity of 2.78% beat GMR Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
GMR Solutions	N/A	N/A	N/A

Summary

InfuSystem beats GMR Solutions on 10 of the 14 factors compared between the two stocks.

How does InfuSystem compare to Fulgent Genetics?

Fulgent Genetics (NASDAQ:FLGT) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by insiders. Comparatively, 10.8% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Fulgent Genetics had 2 more articles in the media than InfuSystem. MarketBeat recorded 3 mentions for Fulgent Genetics and 1 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.63 beat Fulgent Genetics' score of 1.62 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
InfuSystem	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

InfuSystem has lower revenue, but higher earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$323.93M	1.74	-$60.51M	-$2.82	N/A
InfuSystem	$143.34M	1.71	$870K	$0.41	29.63

Fulgent Genetics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

InfuSystem has a net margin of 1.12% compared to Fulgent Genetics' net margin of -26.05%. InfuSystem's return on equity of 2.78% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
InfuSystem	1.12%	2.78%	1.41%

Fulgent Genetics currently has a consensus target price of $27.50, suggesting a potential upside of 34.47%. InfuSystem has a consensus target price of $16.67, suggesting a potential upside of 37.17%. Given InfuSystem's stronger consensus rating and higher probable upside, analysts plainly believe InfuSystem is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

InfuSystem beats Fulgent Genetics on 12 of the 16 factors compared between the two stocks.

How does InfuSystem compare to Strata Critical Medical?

InfuSystem (NYSE:INFU) and Strata Critical Medical (NASDAQ:SRTA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

InfuSystem has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Strata Critical Medical has a beta of 2.26, indicating that its share price is 126% more volatile than the broader market.

InfuSystem currently has a consensus price target of $16.67, indicating a potential upside of 37.17%. Strata Critical Medical has a consensus price target of $8.00, indicating a potential upside of 53.85%. Given Strata Critical Medical's higher probable upside, analysts clearly believe Strata Critical Medical is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Strata Critical Medical	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Strata Critical Medical had 1 more articles in the media than InfuSystem. MarketBeat recorded 2 mentions for Strata Critical Medical and 1 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.63 beat Strata Critical Medical's score of 0.93 indicating that InfuSystem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InfuSystem	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Strata Critical Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Strata Critical Medical has higher revenue and earnings than InfuSystem. Strata Critical Medical is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$143.34M	1.71	$870K	$0.41	29.63
Strata Critical Medical	$197.14M	2.33	$41.35M	-$0.04	N/A

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 47.4% of Strata Critical Medical shares are held by institutional investors. 10.8% of InfuSystem shares are held by company insiders. Comparatively, 15.5% of Strata Critical Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Strata Critical Medical has a net margin of 15.71% compared to InfuSystem's net margin of 1.12%. InfuSystem's return on equity of 2.78% beat Strata Critical Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Strata Critical Medical	15.71%	-2.97%	-2.54%

Summary

Strata Critical Medical beats InfuSystem on 9 of the 16 factors compared between the two stocks.

How does InfuSystem compare to SBC Medical Group?

InfuSystem (NYSE:INFU) and SBC Medical Group (NASDAQ:SBC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

SBC Medical Group has higher revenue and earnings than InfuSystem. SBC Medical Group is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$143.34M	1.71	$870K	$0.41	29.63
SBC Medical Group	$173.61M	2.64	$50.99M	$0.47	9.49

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are held by institutional investors. 10.8% of InfuSystem shares are held by insiders. Comparatively, 81.7% of SBC Medical Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, InfuSystem and InfuSystem both had 1 articles in the media. InfuSystem's average media sentiment score of 1.63 beat SBC Medical Group's score of 1.14 indicating that InfuSystem is being referred to more favorably in the media.

Company	Overall Sentiment
InfuSystem	Very Positive
SBC Medical Group	Positive

InfuSystem presently has a consensus target price of $16.67, indicating a potential upside of 37.17%. SBC Medical Group has a consensus target price of $8.50, indicating a potential upside of 90.58%. Given SBC Medical Group's higher possible upside, analysts clearly believe SBC Medical Group is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
SBC Medical Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

InfuSystem has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

SBC Medical Group has a net margin of 27.99% compared to InfuSystem's net margin of 1.12%. SBC Medical Group's return on equity of 18.47% beat InfuSystem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
SBC Medical Group	27.99%	18.47%	13.10%

Summary

SBC Medical Group beats InfuSystem on 9 of the 15 factors compared between the two stocks.

Get InfuSystem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INFU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INFU vs. The Competition

Export

Metric	InfuSystem	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$244.61M	$9.84B	$7.16B	$23.38B
Dividend Yield	N/A	2.61%	2.57%	3.56%
P/E Ratio	202.53	33.53	274.94	28.72
Price / Sales	1.71	4.89	685.43	21.18
Price / Cash	12.79	125.15	76.65	34.17
Price / Book	4.92	5.29	10.33	4.74
Net Income	$870K	$313.25M	$3.50B	$1.07B
7 Day Performance	-0.74%	-1.26%	-3.32%	-2.00%
1 Month Performance	-2.64%	-1.53%	-0.53%	-3.20%
1 Year Performance	21.62%	58.44%	23.51%	10.51%

InfuSystem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INFU InfuSystem	3.8572 of 5 stars	$12.15 +0.2%	$16.67 +37.2%	+21.6%	$244.61M	$143.34M	202.53	410	Positive News
TALK Talkspace	1.4981 of 5 stars	$5.25 flat	$5.56 +6.0%	N/A	$879.43M	$228.87M	N/A	500
GMRS GMR Solutions	4.5205 of 5 stars	$13.89 +3.2%	$18.67 +34.4%	N/A	$727.13M	N/A	N/A	N/A	News Coverage Positive News Analyst Forecast
FLGT Fulgent Genetics	3.4841 of 5 stars	$20.20 +2.4%	$27.50 +36.1%	-6.5%	$542.88M	$322.67M	N/A	1,315
SRTA Strata Critical Medical	1.9577 of 5 stars	$5.31 -0.2%	$8.00 +50.7%	N/A	$470.64M	$255.98M	N/A	130

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:INFU) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InfuSystem (INFU) Competitors

INFU vs. TALK, GMRS, FLGT, SRTA, and SBC

How does InfuSystem compare to Talkspace?

Summary

How does InfuSystem compare to GMR Solutions?

Summary

How does InfuSystem compare to Fulgent Genetics?

Summary

How does InfuSystem compare to Strata Critical Medical?

Summary

How does InfuSystem compare to SBC Medical Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFU vs. The Competition

InfuSystem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InfuSystem (INFU) Competitors

INFU vs. TALK, GMRS, FLGT, SRTA, and SBC

How does InfuSystem compare to Talkspace?

Which has stronger earnings and valuation, INFU or TALK?

Which has more risk & volatility, INFU or TALK?

Do analysts recommend INFU or TALK?

Do insiders and institutionals believe in INFU or TALK?

Does the media refer more to INFU or TALK?

Is INFU or TALK more profitable?

Summary

How does InfuSystem compare to GMR Solutions?

Do analysts prefer INFU or GMRS?

Which has stronger valuation and earnings, INFU or GMRS?

Does the media refer more to INFU or GMRS?

Do insiders and institutionals believe in INFU or GMRS?

Is INFU or GMRS more profitable?

Summary

How does InfuSystem compare to Fulgent Genetics?

Do insiders & institutionals hold more shares of FLGT or INFU?

Does the media favor FLGT or INFU?

Which has stronger valuation and earnings, FLGT or INFU?

Which has more risk & volatility, FLGT or INFU?

Is FLGT or INFU more profitable?

Do analysts prefer FLGT or INFU?

Summary

How does InfuSystem compare to Strata Critical Medical?

Which has more risk & volatility, INFU or SRTA?

Do analysts rate INFU or SRTA?

Does the media favor INFU or SRTA?

Which has preferable earnings & valuation, INFU or SRTA?

Do insiders & institutionals have more ownership in INFU or SRTA?

Is INFU or SRTA more profitable?

Summary

How does InfuSystem compare to SBC Medical Group?

Which has stronger valuation & earnings, INFU or SBC?

Do insiders and institutionals have more ownership in INFU or SBC?

Does the media refer more to INFU or SBC?

Do analysts rate INFU or SBC?

Which has more volatility & risk, INFU or SBC?

Is INFU or SBC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFU vs. The Competition

InfuSystem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools